Comparison of Outcomes Between Low Dose Emicizumab and Extended Half-life Factor VIII With Pharmacokinetic-guided Prophylaxis in Clinically Severe Hemophilia A
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
* To outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration * To study pharmacokinetic, side effect of low dose Emicizumab
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 3
Maximum Age: 30
Healthy Volunteers: t
View:
• Severe or moderate Hemophilia A with baseline FVIII:C of \<3 IU/dl or severe bleeding phenotype
• Receiving low dose FVIII prophylaxis for at least 6 months
Locations
Other Locations
Thailand
King Chulalongkorn Memorial hospital
RECRUITING
Bangkok
Contact Information
Primary
NUCHANUN KESSAKORN, MD
nuchanun.ks@gmail.com
662-5054639
Time Frame
Start Date: 2023-06-22
Estimated Completion Date: 2024-06-21
Participants
Target number of participants: 15
Treatments
Experimental: low dose emicizumab
2 mg per kilograms per dose in first month, loading every 2 weeks then every 4 weeks
No_intervention: low dose factor VIII prophylaxis
factor VIII prophylaxis
Related Therapeutic Areas
Sponsors
Leads: Chulalongkorn University